Alteogen said on the 26th that it signed an option contract with a global pharmaceutical company for its technology to convert to subcutaneous injection, "ALT-B4."
The counterparty was not disclosed due to product competition dynamics and other reasons. Under the contract, the pharmaceutical company will receive related data to apply Alteogen's ALT-B4 to its currently marketed product and begin clinical development. Alteogen will receive an option fee for this, and the company plans to decide within next year whether to enter into a final technology transfer agreement depending on development progress.
ALT-B4 is a technology that temporarily breaks down hyaluronic acid under the skin to allow administration of high-volume drugs via subcutaneous (SC) injection. It was developed based on Alteogen's proprietary platform "Hybrozyme." Alteogen previously transferred the Hybrozyme platform technology to six global pharmaceutical companies, including Merck (MSD), AstraZeneca, Sandoz, and Daiichi Sankyo.
Separately from this option contract, the company said it is also pursuing a late-stage license agreement with a new partner. The agreement is in the stage of fine-tuning terms, and discussions are underway with the goal of finalizing the deal.